Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Sanofi Signs Agreement to Acquire Colombian Pharmaceutical Company, Genfar

By BiotechDaily International staff writers
Posted on 15 Oct 2012
The French pharmaceutical giant Sanofi (Paris, France signed of a definitive agreement to acquire Genfar SA (Bogota, Colombia).

With this deal signed on October 2, 2012, Sanofi will become a market leader in Colombia and expand its range of cost-effective pharmaceutical agents in Latin America, according to GlobalData (London, UK), an international market research firm. GlobalData believes the race by pharmaceutical companies to establish themselves in the CIVETS (Colombia, Indonesia, Vietnam, Egypt, Turkey, and South Africa) countries might just have begun. With companies such as Eli Lilly and Pfizer already responding to analysts’ calls for prudence about the potential of emerging markets by reducing their forecasts, the CIVETS countries, which are regarded as second-generation emerging markets and holding significant potential, seem to be the next big thing.

Sanofi’s acquisition is one that could generate significant dividends to the company in the future. In an incredibly competitive global pharmaceutical market, the one who moves first can take advantage, which can frequently be a key determinant of success or failure for players in specific geographic markets. As a result, Sanofi could potentially establish itself as a powerhouse with in Colombia and strengthen the barriers to entry for other pharmaceutical companies that may decide to later enter--meaning, according to GlobalData spokespersons, “get in, bolt the door, and lose the key.” Moreover, the company could utilize its entry into Colombia as a starting point for penetrating other CIVETS countries.

Moreover, Sanofi could potentially achieve comparative advantage over its competitors by moving most of its labor-intensive processes to Colombia, and subsequently other second-generation emerging markets. The cost of labor is expected to be significantly lower in these markets than in first-generation emerging markets including China, India, and Brazil. Therefore, by moving into fruitful economies outside of emerging markets, which are destined to become overcrowded at some time because of the swift movement of pharmaceutical companies into them, Sanofi would enjoy reduced costs and consequently, be able to compete on price if the need arises.

According to GlobablData, by acquiring Genfar, Sanofi is jumping into second-generation emerging markets. It will be interesting to see what the pharmaceutical giant will do next.

Related Links:

Sanofi
Genfar
GlobalData



SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: The Human Protein Atlas is tissue-based map of the human proteome (Photo courtesy of the Human Protein Atlas).

Open Source Tissue-Based Map of the Human Proteome Launched

Constructed with 13 million annotated images, an interactive database has been created to show the distribution of proteins in all major tissues and organs of the human body. Ten years after the completion... Read more

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.